XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 6 Months Ended
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues Revenues from collaboration and license agreements as a percentage of total revenues for the three and six months ended June 30, 2023 were as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
20232023
Novartis Institutes for BioMedical Research, Inc.35 %7 %
Biogen MA, Inc.32 %82 %
Kite Pharma, Inc.18 %8 %
Other license agreements15 %3 %
Schedule of Cash and Cash Equivalents
A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):
June 30,
2024		December 31,
2023		June 30,
2023		December 31,
2022
Cash and cash equivalents$27,786 $45,204 $66,830 $100,444 
Non-current restricted cash— 1,500 1,500 1,500 
Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows$27,786 $46,704 $68,330 $101,944 
Restrictions on Cash and Cash Equivalents
A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):
June 30,
2024		December 31,
2023		June 30,
2023		December 31,
2022
Cash and cash equivalents$27,786 $45,204 $66,830 $100,444 
Non-current restricted cash— 1,500 1,500 1,500 
Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows$27,786 $46,704 $68,330 $101,944